Prothena Plc(NASDAQ) PRTA

Prothena Corporation plc makes medicines for people with brain diseases. Its treatments target proteins that cause damage to the body. The company partners with large firms to test these drugs.

A Look at the Pipeline

• Prasinezumab: Investigational antibody designed to block alpha-synuclein protein spread in Parkinson’s disease; developed in partnership with Roche.
• Coramitug: Antibody for ATTR amyloidosis, which is a condition where abnormal proteins build up in the heart and nerves.
• Moponetug: Alzheimer’s disease therapy targeting tau proteins that cause mental decline in patients as the disease progresses.
• PRX012: Treatment for Alzheimer’s disease designed as a once-monthly shot under the skin to clear plaques from the brain.
• PRX019: Early-stage therapeutic for neurodegenerative diseases being evaluated in Phase 1 trials for safety and patient tolerability.

Deals with Global Partners

• Sold the clinical-stage antibody coramitug and the broader ATTR amyloidosis business to Novo Nordisk in July 2021.
• Signed an exclusive global license agreement for moponetug with Bristol Myers Squibb in July 2023.
• Entered into a global license agreement with Bristol Myers Squibb for the PRX019 program in May 2024.
• Initiated the Phase 3 PARAISO clinical trial for Parkinson’s disease in late 2025 through its collaboration with Roche.
• Earned a $50.0 million milestone payment from Novo Nordisk in the six-month period ended June 30, 2026.

Targeting Misfolded Proteins

Prothena uses its CYTOPE technology to deliver treatments directly into the cytosol of cells to reach disease pathways. This method allows the company to target specific proteins that were previously difficult to reach with standard medicine.

Performance by the Numbers

• Total revenue reached $52.1 million for the six months ended June 30, 2026, up 619% year over year.
• Total operating expenses were $43.2 million for the six months ended June 30, 2026, down 73% year over year.
• Cash and cash equivalents totaled $288.2 million as of June 30, 2026.
• Research and development expenses fell to $21.4 million for the six months ended June 30, 2026, down 77% year over year.

Bottom Line

Prothena has evolved from an early research group into a late-stage biotechnology firm with multiple pharmaceutical partnerships. Its focus on protein dysregulation has built a diverse pipeline of candidates for complex neurological and peripheral diseases.